Mesoblast has long been the one poster child for stem cell therapy. Now Cynata and other ASX stocks have e … – Stockhead
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell…
Stem cell therapy, sometimes called regenerative medicine, is one of the most exciting areas of the life sciences sector right now. Since the pandemic, the sector has emerged into the publics spotlight with new developments in mRNA-based vaccines and therapies. Nasdaq is the obvious breeding ground for world-class stem cell companies with the likes of Moderna and BioNTech, and lesser known names like Anavex and Enochian
An Overview of Stem Cell Research | The Center for …
CRANFORD, N.J., Dec. 6, 2021 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies,today announced that it has completed patient enrollment in its Pivotal Phase 3 trial of I/ONTAK, an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL)
The Ethics of Human Cloning and Stem Cell Research …
Post Date: 04/2005, Updated 08/2009Author: CBHD Research Staff In November of 1998, scientists reported that they had successfully isolated and cultured human embryonic stem cellsa feat which had eluded researchers for almost two decades. This announcement kicked off an intense and unrelenting debate between those who approve of embryonic stem cell research and those who are opposed to it. Some of the most prominent advocates of the research are scientists and patients who believe that embryonic stem cell research will lead to the development of treatments and cures for some of humanitys most pernicious afflictions (such as Alzheimers disease, Parkinsons disease, heart disease, and diabetes)
Global Research Antibodies Outlook to 2028: Rise in R&D Initiatives and an Increase in Neurobiology and Stem Cell Research are Key Factors in Market…
"California Cloning: A Dialogue on State Regulation" was convened October 12, 2001, by the Markkula Center for Applied Ethics at Santa Clara University. Its purpose was to bring together experts from the fields of science, religion, ethics, and law to discuss how the state of California should proceed in regulating human cloning and stem cell research. A framework for discussing the issue was provided by Center Director of Biotechnology and Health Care Ethics Margaret McLean, who also serves on the California State Advisory Committee on Human Cloning.
Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (“SPAC”) Enter into Letter of Intent…
Dublin, Dec. 03, 2021 (GLOBE NEWSWIRE) -- The "Global Research Antibodies Market Size, Share & Trends Analysis Report by Product (Primary, Secondary), by Type (Monoclonal Antibodies, Polyclonal Antibodies), by Technology, by Source, by Application, by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
See the original post: Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (“SPAC”) Enter into Letter of Intent...
NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia,…
Continue reading here: Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
Collegium Ranks as a Top Place to Work for 2021 by The Boston Globe
Read this article: NRx Announces Completion of Data Safety Meeting for Phase 2 Trial of BriLife Vaccine, Phase 2b/3 Registration Trial to Begin in Nation of Georgia,...
Read the original: Collegium Ranks as a Top Place to Work for 2021 by The Boston Globe